Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology

Thyroid

Volumn 25, Issue 11, 2015, Pages 1217-1223

  Nikiforov, Yuri E ^a   Carty, Sally E ^a   Chiosea, Simon I ^a   Coyne, Christopher ^a   Duvvuri, Umamaheswar ^a   Ferris, Robert L ^a   Gooding, William E ^a   Lebeau, Shane O ^a   Ohori, N Paul ^a   Seethala, Raja R ^a   Tublin, Mitchell E ^b   Yip, Linwah ^a   Nikiforova, Marina N ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; PARATHYROID HORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PROTEIN RET; RAS PROTEIN;

ARTICLE; ASPIRATION CYTOLOGY; ATYPIA OF UNDETERMINED SIGNIFICANCE; CANCER DIAGNOSIS; CELL COMPOSITION; CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FINE NEEDLE ASPIRATION BIOPSY; FOLLICULAR LESION OF UNDERMINED SIGNIFICANCE; FOLLOW UP; GENE EXPRESSION; GENE FUSION; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MOLECULAR DIAGNOSTICS; NEXT GENERATION SEQUENCING; ONCOGENE H RAS; ONCOGENE N RAS; PARATHYROID CELL; POINT MUTATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THYROID ADENOMA; THYROID FOLLICLE CELL; THYROID FOLLICULAR CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; PATHOLOGY; THYROID GLAND; THYROID NEOPLASMS;

BIOPSY, FINE-NEEDLE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; THYROID GLAND; THYROID NEOPLASMS; THYROID NODULE;

EID: 84946722089     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2015.0305     Document Type: Article

References (22)

1. Gharib H, Goellner JR 1993 Fine-needle aspiration biopsy of the thyroid: An appraisal. Ann Intern Med 118:282-289.
2. Ohori NP, Schoedel KE 2011 Variability in the atypia of undetermined significance/follicular lesion of undetermined significance diagnosis in the bethesda system for reporting thyroid cytopathology: sources and recommendations. Acta Cytol 55:492-498.
3. Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, BalochZW2012 The Bethesda Systemfor Reporting Thyroid Cytopathology: A meta-analysis. Acta Cytol 56:333-339.
4. Ali SZ, Cibas ES 2010 The Bethesda System for Reporting Thyroid Cytopathology. Springer, New York.
5. Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, Vielh P, DeMay RM, Sidawy MK, Frable WJ 2008 Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: A synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 36:425-437.
6. Sosa JA, Hanna JW, Lanman RB, Robinson KA, Ladenson PW 2013 Increases in thyroid nodule fine-needle aspirations, surgeries, and diagnoses of thyroid cancer in the United States. In American Association of Endocrine Surgeons 34th Annual Meeting. Chicago, IL (abstract).
7. Baloch Z, LiVolsi VA, Jain P, Jain R, Aljada I, Mandel S, Langer JE, Gupta PK 2003 Role of repeat fine-needle aspiration biopsy (FNAB) in the management of thyroid nodules. Diagn Cytopathol 29:203-206.
8. Yang J, Schnadig V, Logrono R, Wasserman PG 2007 Fineneedle aspiration of thyroid nodules: A study of 4703 patients with histologic and clinical correlations. Cancer 111:306-315.
9. Nayar R, Ivanovic M 2009 The indeterminate thyroid fineneedle aspiration: experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Cancer 117:195-202.
10. VanderLaan PA, Marqusee E, Krane JF 2011 Clinical outcome for atypia of undetermined significance in thyroid fine-needle aspirations: should repeated fna be the preferred initial approach? Am J Clin Pathol 135:770-775.
11. Adeniran AJ, Hui P, Chhieng DC, Prasad ML, Schofield K, Theoharis C 2011 BRAF mutation testing of thyroid fineneedle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance. Acta Cytol 55:570-575.
12. Kim SK, Hwang TS, Yoo YB, Han HS, Kim DL, Song KH, Lim SD, Kim WS, Paik NS 2011 Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab 96:658-664.
13. Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, Yip L, Seethala RR, Tublin ME, Stang MT, Coyne C, Johnson JT, Stewart AF, Nikiforova MN 2011 Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: A prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 96:3390-3397.
14. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB, Haugen BR 2012 Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 367:705-715.
15. 2013 NCCN Clinical Practice Guidlines in Oncology: Thyroid Carcinoma. National Comprehensive Cancer Network, Fort Washington, PA.
16. McIver B, Castro MR, Morris JC, Bernet V, Smallridge R, Henry M, Kosok L, Reddi H 2014 An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 99:4069-4077.
17. Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, Gooding WE, Hodak SP, LeBeau SO, Ohori NP, Seethala RR, TublinME, Yip L, NikiforovaMN 2014 Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer 120: 3627-3644.
18. Cancer Genome Atlas Research Network 2014 Integrated genomic characterization of papillary thyroid carcinoma. Cell 159:676-690.
19. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW 2nd, Tallini G, Kroll TG, Nikiforov YE 2003 RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88:2318-2326.
20. Ferris RL, Baloch ZW, Bernet V, Chen A, Fahey T, 3rd, Ganly I, Hodak S, Kebebew E, Patel KN, Shaha ARM, Steward D, Tufano RP, Wiseman S, Carty SE 2015 American Thyroid Association statement on surgical application of molecular profiling for thyroid nodules: current impact on perioperative decision making. Thyroid 25: 760-768.
21. Vitagliano D, Portella G, Troncone G, Francione A, Rossi C, Bruno A, Giorgini A, Coluzzi S, Nappi TC, Rothstein JL, Pasquinelli R, Chiappetta G, Terracciano D, Macchia V, Melillo RM, Fusco A, Santoro M 2006 Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. Oncogene 25:5467-5474.
22. Kwak JY, KimEK, MoonHJ, KimMJ, Ahn SS, Son EJ, Sohn YM 2009 Parathyroid incidentalomas detected on routine ultrasound-directed fine-needle aspiration biopsy in patients referred for thyroid nodules and the role of parathyroid hormone analysis in the samples. Thyroid 19:743-748.